Nateglinide

Nateglinide is an orally effective insulin secretagogue derived from D-phenylalanine.it stimulates insulin secretion by inhibiting ATP-sensitive potassium channels in pancreatic β-cells. Nateglinide is apprivrd by FDA for the management of type II diabetes mellitus and is more effective when given preprandially.


Adult Dose
Dose: 120 mg
Single Dose: 120 (120)
Frequency: 8 hourly
Route: PO
Instructions: Should be taken shortly before meal.
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Nateglinide is 317.42.
Contraindications
Nateglinide is contraindicated in conditions like Pregnancy,Breast feeding.
Effects
The symptomatic adverse reactions produced by Nateglinide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Rashes, Urticaria, Pruritus, Hypersensitivity reactions, Hypoglycemia.
Indications
Nateglinide is primarily indicated in conditions like Cardiopulmonary resuscitation, Type II diabetes mellitus.
Interactions
Nateglinide is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementChlorothiazideConcurrent use may reduce the hypoglycemic action of Nateglinide.ClopamideConcurrent use may reduce the hypoglycemic action of Nateglinide.Cortisone (Acetate)Concurrent use may reduce the hypoglycemic action of Nateglinide.DexamethasoneConcurrent use may reduce the hypoglycemic action of Nateglinide.Diclofenac (Na)Concurrent use may potentiate the hypoglycemic action of Nateglinide.EtodolacConcurrent use may potentiate the hypoglycemic action of Nateglinide.FenoprofenConcurrent use may potentiate the hypoglycemic action of Nateglinide.Fludrocortisone (Acetate)Concurrent use may reduce the hypoglycemic action of Nateglinide.VORICONAZOLEVoriconazole may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Paediatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection and trauma) and during surgery; debilitated and malnourished patients; moderate hepatic impairment (avoid if severe).
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.